729-01-1

Basic information

• Product Name: 4'-Nitro-3-biphenylcarboxylic acid
• Synonyms: 4'-Nitro-3-biphenylcarboxylic acid;3-(4-Nitrophenyl)benzoic acid;4-Nitrobiphenyl-3-carboxylic acid;[1,1'-Biphenyl]-3-carboxylicacid, 4'-nitro-
• CAS NO: 729-01-1
• Molecular Formula: C₁₃H₉NO₄
• Molecular Weight: 243.21
• Mol File: 729-01-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4'-Nitro-3-biphenylcarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4'-Nitro-3-biphenylcarboxylic acid(729-01-1)
• EPA Substance Registry System: 4'-Nitro-3-biphenylcarboxylic acid(729-01-1)

Safety Data

• Hazardous Substances Data: 729-01-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
4'-Nitro-3-biphenylcarboxylic acid is used as a key intermediate in the synthesis of various pharmaceutical products. Its unique structure allows it to be a valuable building block for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
As a derivative of biphenyl and carboxylic acid, 4'-Nitro-3-biphenylcarboxylic acid is utilized as a starting material or intermediate in the synthesis of a wide range of organic compounds. Its versatility in chemical reactions makes it a useful component in the creation of complex organic molecules.
Used as a Detection Agent:
4'-Nitro-3-biphenylcarboxylic acid is used as a detection agent for alkali and alkaline earth metal ions. Its chemical properties enable it to selectively interact with these metal ions, making it a valuable tool in analytical chemistry for the identification and quantification of these elements.
Used in Material Science:
4'-Nitro-3-biphenylcarboxylic acid has been studied for its potential use in the design of new materials. Its unique structure and properties may contribute to the development of advanced materials with specific characteristics for various applications in industries such as electronics, aerospace, and automotive.
Used as a Catalyst in Organic Reactions:
4'-Nitro-3-biphenylcarboxylic acid has been investigated for its potential use as a catalyst in organic reactions. Its ability to facilitate chemical transformations can improve the efficiency and selectivity of various organic synthesis processes, making it a valuable asset in the field of catalysis.

Upstream product

• 346-99-6 4-nitro-3'-(trifluoromethyl)-1,1'-biphenyl 
• 366-04-1 3-(trifluoromethyl)biphenyl 
• 351-36-0 N-acetyl-3-trifluoromethylbenzenamine 
• 107558-26-9 methyl 4'-nitro-[1,1'-biphenyl]-3-carboxylate 
• 25487-66-5 3-Carboxyphenylboronic acid 
• 586-78-7 para-nitrophenyl bromide 
• 71-43-2 benzene 
• 87360-24-5 3-amino-benzoic acid methyl ester hydrochloride 
• 16606-00-1 methyl 3-phenylbenzoate 
• 17933-03-8 m-tolylboronic acid 
• 98-07-7 Benzotrichlorid 
• 952-21-6 4-nitro-3'-methylbiphenyl 
• 716-76-7 3-phenylbenzoic acid 

Downstream Products

• 85096-04-4 4'-amino[1,1'-biphenyl]-3-carboxylic acid 
• 62038-00-0 4-nitro-[3-(hydroxymethyl)phenyl]benzene 
• 172542-50-6 4--3-<(triphenylmethyl)thio>propyl>amino>-3'-(tert-butoxycarbonyl)biphenyl 
• 1598408-47-9 1-(4-(3-(1-phenylethylcarbamoyl)phenyl)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea 
• 620963-03-3 1-(4-(3-(Methylcarbamoyl)phenyl)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea 
• 1598408-85-5 C₂₁H₁₈N₂O₃ 
• 1598408-84-4 C₁₄H₁₂N₂O₃ 
• 1598408-66-2 C₂₁H₂₀N₂O 
• 1335041-46-7 C₁₄H₁₄N₂O 
• 1360630-32-5 methyl 4'-(6-carbamoyl-2-naphthamido)biphenyl-3-carboxylate 
• 1360630-30-3 methyl 4'-(2-naphthamido)biphenyl-3-carboxylate 
• 400747-22-0 methyl 4' amino-[1,1'-biphenyl]-3-carboxylate 
• 1360630-56-3 4'-(6-methoxynaphthalene-2-sulfonamido)biphenyl-3-carboxamide 
• 1360630-55-2 methyl 4'-(6-methoxynaphthalene-2-sulfonamido)biphenyl-3-carboxylate 

Relevant articles and documents

Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agents

We report on the virtual screening, synthesis, and biological evaluation of new furan derivatives targeting Mycobacterium tuberculosis salicylate synthase (MbtI). A receptor-based virtual screening procedure was applied to screen the Enamine database, identifying two compounds, I and III, endowed with a good enzyme inhibitory activity. Considering the most active compound I as starting point for the development of novel MbtI inhibitors, we obtained new derivatives based on the furan scaffold. Among the SAR performed on this class, compound 1a emerged as the most potent MbtI inhibitor reported to date (Ki = 5.3 μM). Moreover, compound 1a showed a promising antimycobacterial activity (MIC99 = 156 μM), which is conceivably related to mycobactin biosynthesis inhibition.

Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents

A novel series of diaryl ureas containing different linker groups were designed and synthesized. Their in vitro antitumor activity against MX-1, A375, HepG2, Ketr3 and HT-29 was evaluated using the standard MTT assay. Compounds having a rigid linker group such as vinyl, ethynyl and phenyl showed significant inhibitory activity against a variety of cancer cell lines. Specifically, compound 23 with a phenyl linker group demonstrated broad-spectrum antitumor activity with IC50 values of 5.17-6.46 μM against five tested tumor cell lines. Compound 23 is more potent than reference drug sorafenib (8.27-15.2 μM), representing a promising lead for further optimization.

Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA)

Recent drug discovery programs targeting urokinase plasminogen activator (uPA) have resulted in nonpeptidic inhibitors consisting of amidine or guanidine functional groups attached to aromatic or heteroaromatic scaffolds. There is a general problem of poor oral bioavailability of these charged inhibitors. In this paper, we report the synthesis and evaluation of a series of naphthamide and naphthalene sulfonamides as uPA inhibitors containing non-basic groups as substitute for amidine or guanidine groups.

Biaryl derived amide modulators of vanilloid VR1 receptor

The invention is directed to novel vanilloid receptor type 1 (VR1) ligands. More specifically, the invention relates to novel biaryl-derived amides that are potent antagonists or agonists of VR1. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.

AMINO ACIDS

Compounds of formula (I): Z’ -CO-A-B-NH-Z (I) wherein: Z is H or an amino protecting group; Z’ is OH, a protected or activated hydroxyl group or C1; A is an optionally substituted C5-6 arylene group; and B is an optionally substituted C5-6 arylene group.

Derivatives of aminobenzoic and aminobiphenylcarboxylic acids useful as anti-cancer agents

The present invention provides compounds having the formula: wherein n is0or1; R is —NH2or wherein R1and R2are independently selected from the group consisting of H, alkyl, aralkyl, heteroaralkyl, carboxy, carboxyalkyl, and carbamoyl; Q is R3C(O)— or wherein R5is selected from the group consisting of H, alkyl, aralkyl, heteroaralkyl, and carbamoylalkyl, and R3and R4are selected from the group consisting of H, alkyl, alkoxy, arylalkoxy, aralkyl, heteroaralkyl, and carbamoylalkyl; the Q—NH—(CH2)n— and the —C(O)R substituents of the compound of formula I are independently positioned ortho, meta, orpara relative to the carbon atoms that form the bond between the two phenyl groups to which said substituents are bound, with the proviso that said substituents are not both positioned ortho; and the Q—NH—(CH2)nand the —C(O)R substituents of the compound of formula II are positioned meta orpara to each other; or a biolabile ester thereof, or a pharmaceutically acceptable salt thereof. The compounds are useful for treating uPA- or uPAR-mediated disorders, e.g., tumor metastasis, tumor angiogenesis, restenosis, chronic inflammation, or corneal angiogenesis.

Inhibition of farnesyltransferase

A compound of the formula C0Bwherein C0 stands for A representing O or 2H, and R0 representing SH, NH2, or CxHy-SO2-NH-, wherein CxHy is a straight chain saturated or unsaturated hydrocarbon, with x being between 1 and 20 and y between 3 and 41, inclusive

Inhibitors of prenyl transferases

Compounds which inhibit prenyl transferases, particularly farnysyltransferase and geranylgeranyl transferase I, processes for preparing the compounds, pharmaceutical compositions containing the compounds, and methods of use.

Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors

Cysteine farnesylation of the ras oncogene product Ras is required for its transforming activity and is catalyzed by farnesyltransferase (FTase). The Ras carboxyl terminal tetrapeptide CAAX (C is cysteine, A is any aliphatic amino acid, X is methionine or serine) is the minimum sequence for FTase recognition. We report here the design, synthesis, and biological characterization of Ras CAAX non-peptide mimetics in which the cysteine is linked through a reduced pseudopeptide bond to 4-amino-3'-carboxybiphenyl. These non-peptide mimetics are potent inhibitors of FTase (IC50 = 40 nM for the most potent inhibitor) and are highly selective for FTase over GGTase I (geranylgeranyltransferase I). They are not substrates for farnesylation, do not have peptidic features, and have no hydrolyzable bonds. Structure- activity studies reveal the importance of the position of the carboxylic acid on the aryl ring as well as the reduction of the cysteine amide bond. Substitution at the 2-position of 4-amino-3'-carboxybiphenyl increases inhibitory potency, while the removal of the carboxylic acid results in a 10- fold loss of inhibitory activity.